Lisocabtagene maraleucel is also a CD3-4-1BB CAR T-cell product but it is given at a fixed CD4:CD8 ratio and showed 75% ORR (55% CR) in patients with R/R DLBCL following 2 or more prior therapies, leading to its approval in 2021 for this subgroup (Abramson et al., 2020). Here, CD4 is linked to diffuse large B-cell lymphoma.